ABSTRACT
The use of biological simulation models is likely to play a rapidly increasing role in the coming years as part of the industry’s efforts to continuously improve the pharmaceutical formulation of peptides, proteins, and other drugs and to optimize clinical effect, bioavailability, shelf life, and so on. Models of a similar type are used practically in all other industries and the results are signicant reductions in developing time and costs.
